Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

Saved in:
Bibliographic Details
Title: Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.
Authors: Bondeson DP; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Paolella BR; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Merck Research Laboratories, Cambridge, MA, USA., Asfaw A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rothberg MV; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Skipper TA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Langan C; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mesa G; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gonzalez A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Surface LE; Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ito K; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kazachkova M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Colgan WN; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Warren A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dempster JM; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Krill-Burger JM; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ericsson M; Harvard Medical School, Boston, MA, USA., Tang AA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fung I; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Chambers ES; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Abdusamad M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dumont N; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doench JG; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Piccioni F; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Merck Research Laboratories, Cambridge, MA, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boehm J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hahn WC; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Departments of Pediatric and Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Mannstadt M; Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., McFarland JM; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Vazquez F; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Golub TR; Broad Institute of MIT and Harvard, Cambridge, MA, USA. golub@broadinstitute.org.; Harvard Medical School, Boston, MA, USA. golub@broadinstitute.org.; Departments of Pediatric and Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. golub@broadinstitute.org.
Source: Nature cancer [Nat Cancer] 2022 Jun; Vol. 3 (6), pp. 681-695. Date of Electronic Publication: 2022 Apr 18.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-022-00360-7